Lead Sponsor

GlaxoSmithKline

Age

28 - No limit years

Sex

FEMALE

Healthy Volunteers

Yes

•Written informed consent obtained from the subject prior to enrolment.
•Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
•A subject previously enrolled in the study NCT00294047 and who fulfils either of the following criteria:
•* displayed normal cervical cytology but tested positive for oncogenic HPV infection at her concluding NCT00294047 study visit
•* was pregnant so that no cervical sample could be collected at her concluding NCT00294047 study visit

•A subject who at the NCT00294047 concluding study visit displayed normal cervical cytology and who was negative for oncogenic HPV infection at that visit.
•A subject who at the NCT00294047 concluding study visit had a cervical lesion at that visit or who had a cervical lesion that required treatment at her NCT00294047 exit colposcopy.
•A subject for whom the cervical cytology results from the concluding NCT00294047 study visit were unavailable for reasons other than pregnancy.

Related studies

NCT01627561 · Infections, Papillomavirus

NCT00637195 · Infections, Papillomavirus, Papillomavirus Vaccines

NCT00423046 · Infections, Papillomavirus, Papillomavirus Vaccines

NCT00196937 · Infections, Papillomavirus

NCT01462357 · Infections, Papillomavirus

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects